The global clinical nutrition market size was valued at USD 33.06 billion in 2025 and is projected to grow from USD 34.77 billion in 2026 to USD 52.08 billion by 2034, registering a CAGR of 5.18% during the forecast period from 2026 to 2034. North America dominated the clinical nutrition market with a market share of 38.4% in 2025.
Clinical nutrition refers to the use of specialized nutritional therapies to prevent, manage, and treat diseases or medical conditions. It includes oral nutritional supplements, enteral nutrition, and parenteral nutrition designed to meet the dietary needs of patients in hospitals, clinics, and home care settings. The growing prevalence of chronic diseases, malnutrition, and an aging population is driving the demand for clinical nutrition products and services worldwide.
Download a Free Sample To learn more about this report,
Home Enteral Nutrition Is Expanding Beyond Hospital-Based Care
The clinical nutrition market trends show that growing demand for long-term nutritional support is shifting enteral feeding from hospitals toward home-based care. This transition is supported by dedicated ESPEN guidance for home enteral nutrition, covering patients who require nutritional support outside acute-care settings. The outcome is greater demand for enteral formulas, feeding equipment, and home-based nutrition services.
Micronutrient Management Is Gaining Greater Clinical Attention
The clinical nutrition market trends show that greater focus on nutritional adequacy is shifting clinical care beyond calories and macronutrients toward structured vitamin, mineral, and trace-element management. This transition is reflected in ESPEN's dedicated micronutrient guidance for clinical nutrition, which addresses practical considerations for micronutrient provision. The outcome is stronger demand for specialized micronutrient assessment and supplementation within clinical nutrition programs.
Aging Population and Increasing Surgical Procedures Drive Market
An aging global population is expanding the need for specialized nutritional support because older adults face greater risks of inadequate intake during illness, hospitalization, and recovery. UN DESA projects that the global population aged 65 years and older will exceed 1.6 billion by 2050, creating a larger patient base requiring nutritional management. Hospitals and long-term care facilities can use oral nutritional supplements and specialized formulations to support older patients with reduced appetite or recovery needs. This demographic shift strengthens demand for clinical nutrition products.
A high volume of surgical procedures is creating demand for nutritional support before and after treatment, particularly among patients with prolonged recovery or inadequate oral intake. WHO reports that more than 313 million surgical procedures are performed globally each year, highlighting the scale of the potential clinical nutrition requirement. Perioperative nutrition products can support patients who require additional energy and protein during recovery, while hospitals can integrate these products into surgical care pathways. This sustained procedure volume supports demand for specialized clinical nutrition solutions.
High Product Costs and Patient-Specific Formulation Complexity Restrain Clinical Nutrition Market Expansion
High costs of specialized clinical nutrition products increase the financial burden on patients and healthcare providers, particularly for long-term nutritional support. Higher product and delivery expenses can limit affordability and restrict access in cost-sensitive healthcare settings, slowing wider adoption.
Complex patient-specific formulations require nutritional compositions to be adjusted according to disease conditions, nutrient requirements, and patient tolerance. This customization increases preparation, monitoring, and clinical management requirements, which can raise treatment complexity and limit efficient adoption across healthcare facilities.
Disease-Specific and Sarcopenia-Focused Nutrition Create New Market Opportunities
Medical-food manufacturers, clinical nutrition companies, and healthcare providers can develop specialized formulas for kidney disease, diabetes, gastrointestinal disorders, and other conditions. Companies such as Nestlé Health Science and Abbott can expand their clinical nutrition portfolios through condition-specific products, creating revenue from specialized formulas, hospital contracts, and premium medical-nutrition programs.
Clinical nutrition manufacturers, medical-food developers, and rehabilitation providers can develop protein-rich formulas designed for patients experiencing muscle loss and reduced physical function. Companies such as Abbott and Nestlé Health Science can extend existing nutrition portfolios into sarcopenia-focused products and recovery programs, creating revenue through specialized formulas, clinical partnerships, and rehabilitation-linked nutrition services.
Parenteral Nutrition Supply Disruptions and Limited Access to Specialized Nutrition Care Hinder Clinical Nutrition Market Growth
Parenteral nutrition supply disruptions can interrupt the availability of essential formulations and force healthcare providers to modify treatment plans or rely on alternatives. In September 2026, the FDA reported actions to maintain access to neonatal starter parenteral nutrition after two outsourcing facilities planned closures, highlighting the vulnerability of supply for critical nutrition products.
Limited access to specialized nutrition care restricts the identification, prescription, administration, and monitoring of clinical nutrition therapies, particularly in lower-resource healthcare settings. WHO highlights shortages of trained healthcare professionals and gaps in nutrition-care capacity as continuing barriers to effective nutritional support, limiting adoption of specialized clinical nutrition services.
The oral segment accounted for a share of 53.7% in 2025, supported by its convenience, ease of administration, and suitability for patients requiring nutritional supplementation. The enteral segment supports patients who require nutrition through feeding tubes, while the parenteral segment provides nutritional support when oral or enteral administration is not suitable.
The enteral segment is expected to grow at a CAGR of 7.58% during the forecast period 2026-2034, driven by increasing use of tube-based nutritional support among patients who cannot meet their nutritional requirements through normal oral intake.
Request Customizationto receive a tailored report.
The infant nutrition segment accounted for a share of 42.8% in 2025, reflecting continued demand for specialized nutritional products designed to support infant growth and development. The parental nutrition segment provides nutritional support through intravenous administration, while the enteral nutrition segment supports patients requiring tube-based feeding.
The enteral nutrition segment is expected to grow at a CAGR of 7.48% during the forecast period 2026-2034, fueled by rising demand for specialized nutritional support among patients with impaired swallowing or inadequate oral intake.
The malnutrition segment accounted for a share of 22.4% in 2025 and is expected to grow at a CAGR of 7.76% during the forecast period 2026-2034, supported by increasing demand for nutritional interventions among individuals with inadequate nutrient intake, nutrient deficiencies, or elevated nutritional requirements.
The cancer segment supports nutritional management during cancer treatment, while the neurological diseases segment addresses nutrition needs associated with conditions that can affect eating and nutrient intake. The gastrointestinal disorders segment serves patients with digestive and absorption-related challenges, while the metabolic disorders segment addresses specialized nutritional requirements. The others segment covers additional clinical nutrition applications.
The adults segment accounted for a share of 41.9% in 2025, supported by the broad requirement for clinical nutrition among patients with acute, chronic, and treatment-related nutritional needs. The pediatric segment addresses specialized nutritional requirements during childhood, while the geriatric segment supports nutritional management among older patients.
The geriatric segment is expected to grow at a CAGR of 7.84% during the forecast period 2026-2034, propelled by increasing demand for nutritional support among aging populations and older patients facing greater nutritional challenges.
Speak to an Analystto discuss market opportunities.
The North America clinical nutrition market accounted for the largest regional share of 38.4% in 2025, supported by an aging population, rising prevalence of chronic diseases, growing demand for specialized nutritional support, and increasing adoption of enteral and parenteral nutrition in hospitals and long-term care settings. The U.S. clinical nutrition market is supported by the CDC’s projection that 71.5 million Americans will be aged 65 years or older by 2030, increasing the need for specialized nutritional support as older adults face greater risks of chronic diseases and nutrition-related health needs.
The Canada clinical nutrition market is supported by Statistics Canada projections that people aged 65 and older will account for 21.4%–23.4% of the population by 2030, up from 18.9% in 2023, increasing the potential need for specialized nutritional support among an aging population.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia-Pacific clinical nutrition market is expected to grow at a CAGR of 8.41% during the forecast period 2026-2034, showcasing the fastest-growing regional market, supported by WHO projections that the share of people aged 60 years and above in Southeast Asia will rise to nearly 14% by 2030, increasing demand for nutritional support associated with ageing and chronic health conditions. Japan’s clinical nutrition market is supported by the National Institute of Population and Social Security Research projection that people aged 65 and above will reach 36.65 million, or 31.6% of Japan’s population, by 2030, while Japan’s Ministry of Health, Labour and Welfare projects the 85+ population to continue increasing through around 2035, supporting demand for specialized nutritional and elderly-care products.
China’s clinical nutrition market is supported by the National Nutrition Plan’s target to strengthen clinical nutrition services through 2030, including expanding clinical nutrition departments and achieving a 1:150 ratio of clinical nutritionists to hospital beds, while China’s 2026–2030 health plan targets an average life expectancy of 80 years by 2030, increasing the need for nutrition support among an aging population.
The Europe clinical nutrition market accounted for a 27.6% share in 2025 and is expected to grow at a CAGR of 6.54% during the forecast period 2026-2034, supported by the European Commission’s focus on healthy ageing, nutrition, and the development of tailored dietary solutions for older populations, including those at risk of malnutrition. The U.K. clinical nutrition market is supported by Cancer Research UK projections that more than 505,000 new cancer cases could be recorded annually by 2038–2040, increasing the potential need for clinical nutritional support among patients undergoing cancer treatment and recovery.
Germany’s clinical nutrition market is supported by Destatis projections that the number of people aged 67 and above will rise to at least 20.5 million by the end of the 2030s, increasing the need for nutritional support associated with ageing and healthcare.
The clinical nutrition market competitive landscape is moderately consolidated, with competition comprising specialized medical nutrition companies, pharmaceutical and healthcare companies, enteral and parenteral nutrition providers, and nutritional supplement manufacturers. Key players such as Abbott Laboratories, B. Braun Melsungen AG, Danone Nutricia, Baxter International Inc., and Fresenius SE & Co. KGaA collectively are estimated to account for approximately 55–60% of the global clinical nutrition market share.
Established players compete primarily on product portfolio breadth, clinical evidence, formulation capabilities, and distribution networks. Emerging and specialized players in the clinical nutrition market ecosystem compete through disease-specific formulations, personalized nutrition solutions, specialized pediatric products, and home-based nutrition services. Abbott offers adult and pediatric nutritional products, while B. Braun and Fresenius Kabi provide enteral and parenteral nutrition solutions for hospital and home-care settings.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Phenylketonuria Market Size, Share, Growth, Analysis, Report, 2034
Ovarian Cancer Market Size, Share, Growth, Analysis, Report, 2034
Tulathromycin Market Size, Share, Growth, Analysis, Report, 2034
Renal Replacement Therapy Market Size, Share, Growth, 2034
Advanced Cancer Pain Management Market Size, Share, 2034
Facial Injectable Market Size, Share, Growth, Forecast, 2034
We are featured on:
sales@straitsresearch.com